...ly invasive surgery is founded on superior medical...-Chip cameras, 1-Chip cameras, Light sources, Coup...nding needs., ,Superior resolution and color repr...meras, and are the benchmark by which all other me...
...ra System provides easy-to-use features, auto iris...amera head construction is based on Solos durable ...era System, International (GS9900-PAL) includes: ,...rd and video cables , (GS 9905) Camera head with 3...
Provides a combination of concentrated cold / hot and compression for the elbow
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery.
Medicine Products:(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2(Date:10/13/2008)...e/ -- Neuronascent, Inc.,( http://www.neuronascent...ed,funding from multiple sources to further the de...ting Alzheimer,s disease, depression and,ischemia.... Maryland,Department of Business and Economic Deve...ustrial Partnerships in collaboration with Univers...
(Date:10/13/2008)...Higher Sensitivity and Specificity, than Other Ra...referred test in all phases of thi...wswire/ -- AT First Diagnostic LLC an,emerging wor...its, today,announced that a recent evaluation cond...h of the FirstVue(TM) HBSAG Test, was released at ...
(Date:10/13/2008)...e Cancer Populations Facilitates ... 13 /- Rubicon Genomics, Inc. today,a...fy DNA samples for The,Cancer Atlas Genome Project...tandardize total genomic,DNA from 3,000 tissue and...enomePlex(TM) Whole Genome Amplification technolog...
(Date:10/12/2008)...ombination with Chemotherapy, FREMONT, Calif. Oct...a,development-stage pharmaceutical company discove...based therapeutics, today announced that the,journ...f siRNA targeting,its proprietary target gene agai...ion dated October 1, 2008. The paper, entitled "RN...
Breaking Medicine Technology:Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 1841 1PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 1841 2Riley Hospital for Children 26amp 3B Capital Institute of Pediatrics become international sister hospitals 17105 1Riley Hospital for Children 26amp 3B Capital Institute of Pediatrics become international sister hospitals 17105 2Researchers evaluating food allergy treatment 17102 1Researchers evaluating food allergy treatment 17102 2Inaugural Kirkham Gold Medal presented to expert on soil physics 2942 1Inaugural Kirkham Gold Medal presented to expert on soil physics 2942 2...One Month Study in Seventy Type 2 Diabetes Patient...hnologies Inc.,(TSX:CJB) today announced positiv...le-dose clinical study for the treatment of Type 2...(TM):Exendin-4.,Results from the study demonstra... tolerated and, when administered once-weekly at e...
...VERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inot... presentation of,positive Phase 2 clinical data de...potential for INO-1001 as a preventative agent for...ed in subjects,with acute ST-elevated myocardial i...coronary intervention. The presentation was,made i...
Other Medicine Technology:PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4